Agenix Limited [ASX: AGX, OTC (NASDAQ): AGXLY] is a biopharmaceutical company based in Brisbane, Australia. Through its wholly owned subsidiaries, Agen Biomedical and Agenix Biopharmaceutical (Shanghai), the company has a strategic goal of building and developing a pipeline of therapeutic and imaging products.

Inovio Biomedical Corporation [AMEX: INO] is focused on the development of next-generation vaccines and vaccine delivery methods to prevent or treat cancers and chronic infectious diseases.

Auricle Biomedical Corporation is a public capital pool company. The Company is engaged in identifying a promising private medical device company into which it can merge with Auricle and become a public entity.

Prospiva Capital (VCC) Inc. is a Venture Capital Corporation that raises money from investors and invests, in accordance with the Government of British Columbia’s Small Business Venture Capital Act, into late-stage start-up companies in BC with a particular focus on medical technologies.

Auricle Biomedical Corporation

enGene is an emerging, preclinical-stage biotechnology company that is developing a unique method of protein drug delivery called GEMS (Gut Endocrine-cell Modification System).  GEMS has the potential to provide regulated, effective, long-term treatment for serious chronic diseases such as diabetes, obesity, anemia, inflammatory bowel disease, bone disorders and hemophilia.